Pierre Youinou
Research Subjects
Pierre Youinou has a total of 224 co-authors. Here are the top co-authors by number of shared publications:
- Yves Renaudineau
Referral Medical Biology Laboratory, Department of Immunology, Toulouse University Hospital Center, University of Toulouse, 330 Avenue de Grande-Bretagne, 31000 Toulouse, France
24 shared publications P Le Goff
22 shared publicationsY Pennec
22 shared publicationsA Saraux
19 shared publicationsJacques-Olivier Pers
EA2216, Inserm ESPRI, ERI29, "Immunology and Pathology", Laboratoire d'Immunologie, CHRU Morvan, 29609 Brest cedex, France
18 shared publicationsChristophe Jamin
EA2216 Immunologie et Pathologie, LabEx IGO, SFR ScInBioS, Université de Brest et Université Européenne de Bretagne, Brest, France
16 shared publications
Latest Publications
- 1 March 2015
- Published by Elsevier in Joint Bone Spine
- Vol. 82 (2) , 75-76
Primary Sjögren's syndrome at a glance today
- 1 March 2015
- Published by Elsevier in Joint Bone Spine
- Vol. 82 (2) , 75-76
Primary Sjögren's syndrome at a glance today
- 1 April 2014
- Published by Elsevier in Autoimmunity Reviews
- Vol. 13 (4-5) , 574-576
Diagnostic criteria for autoimmune neutropenia
- 1 April 2014
- Published by Elsevier in Autoimmunity Reviews
- Vol. 13 (4-5) , 574-576
Diagnostic criteria for autoimmune neutropenia
- Open Access
- 12 September 2012
- Published by SAGE Publications in Lupus
- Vol. 21 (13) , 1375-1377
B lymphocytes in nonorgan-specific autoimmune diseases: implications for therapy
- 12 September 2012
- Published by SAGE Publications in Lupus
- Vol. 21 (13) , 1375-1377
Open AccessB lymphocytes in nonorgan-specific autoimmune diseases: implications for therapy
- 31 July 2012
- Published by Elsevier in La Presse Médicale
- Vol. 41 (9) , e437-e439
Latest update on the primary Sjögren's syndrome
- 31 July 2012
- Published by Elsevier in La Presse Médicale
- Vol. 41 (9) , e437-e439
Latest update on the primary Sjögren's syndrome
- 1 July 2012
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 13 (10) , 2071-2077
B-Lymphocytes Govern the Pathogenesis of Sjogren's Syndrome
T cells have originally occupied central stage of the debate on the type of lymphocytes governing the pathogenesis of Sjögren’s syndrome (SS). However, B cells has since been substituted for T cells, and insights into their functions have revealed that they accomplish various tasks. Beyond the paradigm that T lymphocytes maintain strict control over B lymphocytes, these latter cells solicit their own help from the former, release a flurry of cytokines, and act as antigen- presenting cells. In SS, excessive of the B cell-activating factor (BAFF) may cause B-cell quantitative anomalies, such as inflation of mature B (Bm)2/Bm2’ cells in the circulation, or accumulation of transitional type 2, marginal zone (MZ) and memory B cells within the exocrine gland infiltrates. These excesses are also associated with B-cell qualitative anomalies, such as the internal synthesis of BAFF, and a default mechanism that promotes the autoantibody production in ectopic germinal centers or MZ equivalents. Thus, SS should rather be conceived as a quintessential model for B cellinduced autoimmunity. Such a view opens novel prospects for treatment, and indeed B cell-ablative therapy has already been shown to be beneficial to these patients.
- 1 July 2012
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 13 (10) , 2071-2077
B-Lymphocytes Govern the Pathogenesis of Sjogren's Syndrome
T cells have originally occupied central stage of the debate on the type of lymphocytes governing the pathogenesis of Sjögren’s syndrome (SS). However, B cells has since been substituted for T cells, and insights into their functions have revealed that they accomplish various tasks. Beyond the paradigm that T lymphocytes maintain strict control over B lymphocytes, these latter cells solicit their own help from the former, release a flurry of cytokines, and act as antigen- presenting cells. In SS, excessive of the B cell-activating factor (BAFF) may cause B-cell quantitative anomalies, such as inflation of mature B (Bm)2/Bm2’ cells in the circulation, or accumulation of transitional type 2, marginal zone (MZ) and memory B cells within the exocrine gland infiltrates. These excesses are also associated with B-cell qualitative anomalies, such as the internal synthesis of BAFF, and a default mechanism that promotes the autoantibody production in ectopic germinal centers or MZ equivalents. Thus, SS should rather be conceived as a quintessential model for B cellinduced autoimmunity. Such a view opens novel prospects for treatment, and indeed B cell-ablative therapy has already been shown to be beneficial to these patients.
- Open Access
- 5 January 2012
- Published by American Society of Hematology in Blood
- Vol. 119 (1) , 106-114
Maturation and function of human dendritic cells are regulated by B lymphocytes
Mature dendritic cells (DCs) are stimulators of T-cell immune response, whereas immature DCs support T-cell tolerance. Murine B cells can inhibit the production of IL-12 by DCs and thereby hinder the inflammatory response. Notwithstanding the importance of this modulation, only a few studies are available in humans. Here, we have developed an in vitro model of cocultures to assess its significance. We establish that human activated B cells restrained the development of monocytes into immature DCs and their differentiation into mature DCs. In addition, they decreased the density of HLA-DR from mature DCs, the expression of CD80 and CD86 coactivation molecules, the production of IL-12p70 required for antigen presentation and Th1 differentiation, and inhibited the DC-induced T-cell proliferation. These modulations were mediated by CD19+IgDlowCD38+CD24lowCD27− B cells and needed direct cell-to-cell contacts that involved CD62L for the control of CD80 and CD86 expression and a soluble factor for the control of IL-12 production. Moreover, mature DCs from patients with systemic lupus erythematosus displayed insensitivity to the regulation of IL-12. Overall, it appears that human B cells can regulate DC maturation and function and that inefficient B-cell regulation may influence an improper balance between an effector inflammatory response and tolerance induction.
- 5 January 2012
- Published by American Society of Hematology in Blood
- Vol. 119 (1) , 106-114
Open AccessMaturation and function of human dendritic cells are regulated by B lymphocytes
Mature dendritic cells (DCs) are stimulators of T-cell immune response, whereas immature DCs support T-cell tolerance. Murine B cells can inhibit the production of IL-12 by DCs and thereby hinder the inflammatory response. Notwithstanding the importance of this modulation, only a few studies are available in humans. Here, we have developed an in vitro model of cocultures to assess its significance. We establish that human activated B cells restrained the development of monocytes into immature DCs and their differentiation into mature DCs. In addition, they decreased the density of HLA-DR from mature DCs, the expression of CD80 and CD86 coactivation molecules, the production of IL-12p70 required for antigen presentation and Th1 differentiation, and inhibited the DC-induced T-cell proliferation. These modulations were mediated by CD19+IgDlowCD38+CD24lowCD27− B cells and needed direct cell-to-cell contacts that involved CD62L for the control of CD80 and CD86 expression and a soluble factor for the control of IL-12 production. Moreover, mature DCs from patients with systemic lupus erythematosus displayed insensitivity to the regulation of IL-12. Overall, it appears that human B cells can regulate DC maturation and function and that inefficient B-cell regulation may influence an improper balance between an effector inflammatory response and tolerance induction.
- Open Access
- 28 November 2011
- Published by Wiley in Journal of Immunology Research
- Vol. 2012, 1-8
Mesangial Cell-Specific Antibodies Are Central to the Pathogenesis of Lupus Nephritis
Not only is nephritis a common complaint in systemic lupus erythematosus, but it is also the most life-threatening complication of the disease. Anti-double-stranded DNA antibodies (Abs), which are found in up to 80% of these patients, might be nephritogenic per se. That is, they may cross-react with mesangial cell (MC) surface proteins, such as alpha-actinin and annexin A2, they may cross-react with mesangial matrix protein such as laminine and fibronectin, or they may recognize chromatin material previously deposited in the glomeruli. The consequence of the binding of anti-MC Abs may be their internalization, which results in activation and proliferation of these MCs. In turn, these activated MCs are suspected of promoting immune complex formation by sequestering and thereby protecting chromatin from degradation. The present paper will explain the mechanisms through which such autoAbs may initiate nephritis.
- 28 November 2011
- Published by Wiley in Journal of Immunology Research
- Vol. 2012, 1-8
Open AccessMesangial Cell-Specific Antibodies Are Central to the Pathogenesis of Lupus Nephritis
Not only is nephritis a common complaint in systemic lupus erythematosus, but it is also the most life-threatening complication of the disease. Anti-double-stranded DNA antibodies (Abs), which are found in up to 80% of these patients, might be nephritogenic per se. That is, they may cross-react with mesangial cell (MC) surface proteins, such as alpha-actinin and annexin A2, they may cross-react with mesangial matrix protein such as laminine and fibronectin, or they may recognize chromatin material previously deposited in the glomeruli. The consequence of the binding of anti-MC Abs may be their internalization, which results in activation and proliferation of these MCs. In turn, these activated MCs are suspected of promoting immune complex formation by sequestering and thereby protecting chromatin from degradation. The present paper will explain the mechanisms through which such autoAbs may initiate nephritis.
- 22 November 2011
- Vol. 50 (2) , 16-7
Intravenous immunoglobulin induces anergy statelike of auto-reactive B lymphocytes in Sjögren's syndrome.
- 22 November 2011
- Vol. 50 (2) , 16-7
Intravenous immunoglobulin induces anergy statelike of auto-reactive B lymphocytes in Sjögren's syndrome.
- 22 November 2011
- Vol. 50 (2) , 21-2
Toll-like receptor 9 drives the maturation of B lymphocytes in the salivary glands of patients with Sjögren's syndrome.
- 22 November 2011
- Vol. 50 (2) , 21-2
Toll-like receptor 9 drives the maturation of B lymphocytes in the salivary glands of patients with Sjögren's syndrome.
- 22 November 2011
- Vol. 50 (2) , 165
B lymphocytes induce epithelial cells of salivary glands into apoptosis through protein kinase C delta activation.
- 22 November 2011
- Vol. 50 (2) , 165
B lymphocytes induce epithelial cells of salivary glands into apoptosis through protein kinase C delta activation.